Recent Updates — OCGN
The company disclosed that the Bahamas Regulatory Agency provided provisional approval and priority designation for its gene therapy candidate OCU400, enabling an Early Access Program (EAP) with commercial pricing. Ocugen anticipates full LARTA approval within 90 days to begin patient dosing globally, potentially generating $1-2 million per patient in revenue ahead of major market approvals. The presentation also highlighted ongoing Phase 3 trials for OCU400 targeting retinitis pigmentosa and OCU410ST for Stargardt disease, alongside the recent initiation of a Phase 3 trial for geographic atrophy (OCU410). Ocugen is a biotechnology company developing gene therapies to treat blindness.
Ocugen entered into an exclusive license agreement with Roots Pharmaceutical Company WLL, granting rights to commercialize its modifier gene therapy OCU400 for retinitis pigmentosa in the Middle East and North Africa. Under the deal, Ocugen will receive up to $4 million in upfront and development milestones, plus up to $255 million in sales milestones, along with a 22% royalty on net sales. Ocugen retains global safety database ownership and will manufacture commercial supply under a separate agreement. Concurrently, Ocugen postponed its Special Meeting of Stockholders scheduled for December 22, 2026, specifically regarding the proposal to increase authorized common stock by 250 million shares, allowing additional time for shareholder consideration. Ocugen is a biotechnology company developing gene therapies for blindness diseases.
Ocugen reconvened its Special Meeting of Stockholders on October 5, 2026, but adjourned the meeting solely regarding Proposal 1. The proposal seeks to amend the Company’s Sixth Amended and Restated Certificate of Incorporation to increase the number of authorized shares of common stock by 250,000,000 shares. The Adjourned Meeting is scheduled for October 26, 2026, at 8:00 a.m. Eastern Time. The record date remains July 27, 2026. Ocugen operates in the biotechnology industry, focusing on gene therapy and vaccine development.
On September 1, 2026, Ocugen announced the first patient was dosed in the global Phase 3 registrational trial of OCU410, a gene therapy candidate for Geographic Atrophy secondary to dry age-related macular degeneration. This follows FDA alignment on pivotal trial design and RMAT designation granted in July 2026. Separately, on September 3, 2026, the independent Data Monitoring Committee recommended continuing the Phase 2/3 OCU410ST trial for Stargardt disease to obtain eight-month follow-up data on the entire population, despite interim results showing a negative direction of treatment effect that could suggest futility. Ocugen operates in the biotechnology industry and develops gene therapies for inherited retinal diseases.
Ocugen reported a net loss of $0.07 per share for the quarter ended June 30, 2026, with operating expenses rising to $17.9 million from $15.2 million in the prior year period. The company closed a $130.0 million convertible senior notes financing, generating approximately $112.5 million in net proceeds, which it used to fully retire its Avenue Capital loan and extend its cash runway into 2028. Cash reserves increased to $100.4 million as of June 30, 2026. Clinically, Ocugen received FDA clearance to initiate the Phase 3 ArMaDa trial for OCU410 in geographic atrophy and was granted RMAT designation for the same program. The company also signed a binding term sheet with Roots Pharmaceutical for an exclusive license of OCU400 in the MENA region, featuring up to $255 million in sales milestones. Ocugen appointed Mohamed Genead as Chief Medical Officer and Chris Clark as Head of Corporate Communications. Ocugen is a biotechnology company developing gene therapies for blindness diseases.